Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and...
Cervical CancerVulvar Cancer3 moreThis study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4 weeks postdose 3 are non-inferior in adult women as compared with GMTs in young adult women.
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese...
Cervical CancerVulvar Cancer12 moreThe study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Human Papilloma VirusCervical Cancer3 moreThis study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX). Reviews of safety and tolerability will be used to select the dose(s) of IMX for further studies of the octavalent HPV L1 VLP vaccine.
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females...
HPV InfectionsCervical Cancer13 moreThe study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Cervical CancerVulvar Cancer3 moreThe purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component...
Cervical CancerGenital WartsThe purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine...
HPV InfectionsCervical Cancer Stage IIa5 moreTo access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
Human Papilloma Virus Infection Type 11Human Papilloma Virus Infection Type 165 morePrimary, Secondary, and Exploratory Objective(s): Primary objective: To evaluate the effect of interventions on 1st dose uptake of HPV vaccine.
Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital...
External Genital WartsThe purpose of this double blind study is to determine whether topical 15% AS101 gel is effective and safe as compared to vehicle in the treatment of external genital warts in women.
Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple...
Genital Wart Virus InfectionIn order to determine the Efficacy of Betaglucin 0.2% in gel vs Imiquimod 5% cream in the treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51 with Betaglucin 0.2% and 51 with Imiquimod 5%.
